文献速递冠心病心力衰竭与心肌病

主动脉内球囊反搏在急性心肌梗死合并心源性休克中的6年长期结局:IABP-SHOCK II随机试验

Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial.
PubMed 文献 · Circulation · 2018-11-11

IABP-SHOCK II试验为多中心随机开放标签研究,纳入600例急性心肌梗死合并心源性休克并接受早期血运重建的患者,随机分为IABP组与对照组。6.2年随访显示两组全因死亡率无差异(66.3% vs 67.0%;RR 0.99;95%CI 0.88-1.11;P=0.98),再发心梗、卒中、再次血运重建及心脏原因再住院亦无差异,幸存者生活质量与NYHA分级无差异。尽管当代血运重建治疗,心源性休克死亡率仍高达约三分之二。

要点

  • IABP对急性心梗合并心源性休克患者6年全因死亡率无影响。
  • 两组再发心梗、卒中、再次血运重建及心脏原因再住院均无差异。
  • 幸存者生活质量(EuroQol 5D)与NYHA分级在两组间无差异。

核心结论

  • 在急性心肌梗死合并心源性休克并接受早期血运重建的患者中,IABP对6年长期随访的全因死亡率无影响。
  • 尽管采用当代血运重建治疗,心源性休克患者死亡率仍很高,约三分之二患者死亡。

研究设计与样本

  • IABP-SHOCK II试验为多中心、随机、开放标签试验,于2009至2012年间纳入600例急性心肌梗死合并心源性休克并接受早期血运重建的患者,随机分为IABP组与对照组。
  • 长期随访在初始随机化后6.2年(四分位距5.6-6.7)进行,600例中591例(98.5%)完成随访。

主要发现

  • IABP组与对照组全因死亡率无差异(66.3% vs 67.0%;相对风险0.99;95%CI 0.88-1.11;P=0.98)。
  • 两组再发心肌梗死、卒中、再次血运重建或心脏原因再住院均无差异(所有P>0.05)。
  • 幸存者经EuroQol 5D问卷评估的生活质量及NYHA分级在两组间无差异。

临床怎么用

  • 对于急性心肌梗死合并心源性休克并接受早期血运重建的患者,不应期望IABP改善长期生存。
  • 与患者及家属沟通预后时,应告知即使采用当代血运重建治疗,心源性休克长期死亡率仍约三分之二。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of intraaortic balloon counterpulsation (IABP) in cardiogenic shock is still a subject of intense debate despite the neutral results of the IABP-SHOCK II trial (Intraaortic Balloon Pump in Cardiogenic Shock II) with subsequent downgrading in international guidelines. So far, randomized data on the impact of IABP on long-term clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction are lacking. Furthermore, only limited evidence is available on general long-term outcomes of patients with cardiogenic shock treated by contemporary practice. METHODS: The IABP-SHOCK II trial is a multicenter, randomized, open-label trial. Between 2009 and 2012, 600 patients with cardiogenic shock complicating acute myocardial infarction undergoing early revascularization were randomized to IABP versus control. RESULTS: Long-term follow-up was performed 6.2 years (interquartile range 5.6-6.7) after initial randomization. Follow-up was completed for 591 of 600 patients (98.5%). Mortality was not different between the IABP and the control group (66.3% versus 67.0%; relative risk, 0.99; 95% CI, 0.88-1.11; P=0.98). There were also no differences in recurrent myocardial infarction, stroke, repeat revascularization, or rehospitalization for cardiac reasons (all P>0.05). Survivors' quality of life as assessed by the EuroQol 5D questionnaire and the New York Heart Association class did not differ between groups. CONCLUSIONS: IABP has no effect on all-cause mortality at 6-year long-term follow-up. Mortality is still very high, with two thirds of patients with cardiogenic shock dying despite contemporary treatment with revascularization therapy. CLINICAL TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov/. Unique identifier: NCT00491036.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Thiele H, Zeymer U, Thelemann N, et al. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial. Circulation. 2018. PMID: 30586721. doi:10.1161/CIRCULATIONAHA.118.038201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。